European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma ...

Edit Stockhouse 14 Sep 2016
Regulatory News.. Ipsen (Euronext.IPN; ADR.IPSEY), a global specialty-driven pharmaceutical group, today announced that the European Commission has approved Cabometyx™ (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy ... David Meek, Chief Executive Officer, Ipsen stated ... Dr ... ” ... On April 25, 2016, the U.S ... Oncogene....

European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy (Exelixis Inc)

Edit Public Technologies 14 Sep 2016
(Source. Exelixis Inc). - CABOMETYX is the first and only therapy approved in the European Union to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial of patients with advanced kidney cancer -. - Approval of CABOMETYX in European Union triggers $60 million milestone payment to Exelixis under licensing agreement with Ipsen - ... 14, 2016-- Exelixis, Inc ... Oncogene....

European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following ...

Edit Stockhouse 14 Sep 2016
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy. – CABOMETYX is the first and only therapy approved in the European Union to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial of patients with advanced kidney cancer – ... Exelixis, Inc ... 6 ... U.S ... 1 ... 2 ... 3 ... 4 ... Oncogene....

La Commission européenne accorde l’autorisation de mise sur le marché pour Cabometyx™ comprimés (cabozantinib) d’Ipsen ...

Edit Stockhouse 14 Sep 2016
La Commission européenne accorde l’autorisation de mise sur le marché pour Cabometyx™ comprimés (cabozantinib) d’Ipsen dans le traitement du cancer du rein avancé de l'adulte... Regulatory News. ... Ipsen (Euronext . IPN ; ADR  ... David Meek, Directeur général d'Ipsen a déclaré  ... ». Cette autorisation s'appuie sur les résultats de METEOR, une vaste étude de phase 3 randomisée. À propos de CABOMETYX™ (cabozantinib) ... 1 ... Oncogene....

Prostate Cancer UK awards researchers crucial grant for pioneering prostate cancer study (University of the West of England)

Edit Public Technologies 09 Sep 2016
New research led by Michael Ladomery at the University of the West of England, (UWE Bristol) will aim to develop SSOs ('splice switching oligonucleotides') that will specifically target a gene, known as oncogene ERG, which is inappropriately activated in 50% of prostate cancers ... Remarkably the ERG oncogene is activated in 50% of prostate cancers - one of the most notable associations of any given gene with a specific type of cancer....

Mount Sinai Researchers Identify New Therapeutic Target for Cancer (Mount Sinai Hospital)

Edit Public Technologies 09 Sep 2016
(Source. Mount Sinai Hospital). New York, NY - September 9, 2016 /Press Release/ -- ... Ras is the most frequently mutated human cancer gene (oncogene), yet despite recent breakthroughs, therapeutic options to target Ras-dependent cancers remain limited. Previous studies had supported the possibility of targeting oncogenic forms of Ras via KSR, but no pharmacological approaches had been reported until now ... Dar explained ... News & World Report....

Trovagene to Present at the 3rd Annual Precision Medicine Congress (TrovaGene Inc)

Edit Public Technologies 09 Sep 2016
(Source. TrovaGene Inc). SAN DIEGO, Sept. 9, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ ... Dr. Erlander is scheduled to present on Monday, September 12, 2016at 11.50 am BST ... Presentation Highlights ... About the 3rd Annual Precision Medicine Congress ... About Trovagene, Inc ... The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management ... Forward Looking Statements ... SOURCE Trovagene, Inc ... (noodl....

‘Forgotten molecule’ takes centre stage in cancer gene silencing (The Garvan Institute of Medical Research)

Edit Public Technologies 08 Sep 2016
(Source. The Garvan Institute of Medical Research) ... Their findings, which have been published online this week in the journal Oncogene, help explain the molecular events that lead to the silencing of key tumour-suppressor genes in cancer cells - and show that the MBD2 protein, which binds to methylated DNA sequences, also plays a wide-ranging role in guiding the process of DNA methylation ... (noodl. 35260504) ....

Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016

Edit Stockhouse 06 Sep 2016
MYCN is an important therapeutic target in oncology and a major oncogenic driver of neuroblastoma, a childhood cancer ... The MYCN oncogene is over-expressed in a number of different types of cancer, most notably neuroblastoma, and also rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms' tumor and small cell lung cancer....

2-Sulfonylpyrimidines target p53-compromised cells [Biochemistry]>

Edit PNAS 06 Sep 2016
The tumor suppressor p53 has the most frequently mutated gene in human cancers. Many of p53’s oncogenic mutants are just destabilized and rapidly aggregate, and are targets for stabilization by drugs. We found certain 2-sulfonylpyrimidines, including one named PK11007, to be mild thiol alkylators with anticancer activity in several cell... ....

Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 (Cyclacel Pharmaceuticals Inc)

Edit Public Technologies 06 Sep 2016
MYCN is an important therapeutic target in oncology and a major oncogenic driver of neuroblastoma, a childhood cancer ... The MYCN oncogene is over-expressed in a number of different types of cancer, most notably neuroblastoma, and also rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms' tumor and small cell lung cancer....

New oncogene linked to prostate cancer in African Americans may lead to better diagnostic tools, treatments (Baylor College of Medicine)

Edit Public Technologies 04 Sep 2016
A team of scientists has identified MNX1 as a new oncogene - a gene than can cause cancer - that is more active in African American prostate cancer than in European American prostate cancer ... 'Some of the genes were less active in African American prostate cancer, but we concentrated on those that were more active as they could potentially be oncogenes ... 'Our study so far suggested that MNX1 was likely an oncogene in prostate cancer....

Epizyme to Present at Upcoming Investor Conferences

Edit Stockhouse 01 Sep 2016
CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ.EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at three investor conferences in September. ... Genetic alterations can result in changes to the activity of CMPs, making them oncogenic (cancer-causing) ... ....
×